Whiteside & Goldberg representing victims in Invokana and Invokamet (SGLT2) cases
In May of 2015, the Federal Drug Administration released a warning that certain Type 2 diabetes drugs, classified as SGLT2 inhibitors, may result in a serious condition of too much acid in the blood. The medicines described in the warning are canagliflozin, dapagliflozin and empagliflozin, which may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization. The brand name of these drugs include Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance, and Glyxambi.
Whiteside & Goldberg, Ltd. is currently representing victims who have taken these drugs and have developed ketoacidosis as a result of the harmful side effects of these drugs. Some other potential harmful side effects include a risk of stroke, blood infection and urinary tract infections. Please feel free to contact the law firm of Whiteside & Goldberg, Ltd. for a free consultation if you have suffered these symptoms as a result of taking this class of medication. You can call us (312) 334-6875 or email us at email@example.com
The content of this blog is intended for informational purposes only and does not constitute or establish an attorney-client relationship, nor constitute legal advice. If you wish to discuss any further aspect of the material contained herein, please contact an attorney at Whiteside & Goldberg, Ltd.